Matthew A Rank1, Juliette T Liesinger2, Jeanette Y Ziegenfuss2, Megan E Branda2, Kaiser G Lim3, Barbara P Yawn4, Nilay D Shah2. 1. Division of Allergic Diseases, Olmsted Medical Center, Rochester, MN. Electronic address: rank.matthew@mayo.edu. 2. Division of Health Care Policy and Research, Olmsted Medical Center, Rochester, MN. 3. Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Olmsted Medical Center, Rochester, MN. 4. Department of Research, Olmsted Medical Center, Rochester, MN.
Abstract
BACKGROUND: The relationship between asthma controller medication use and exacerbation rates over time is unclear at the population level. OBJECTIVE: To estimate the change in asthma controller medication use between 2 time periods as measured by the controller-to-total asthma medication ratio and its association with changes in asthma exacerbation rates between 1997-1998 and 2004-2005. METHODS: The study design was a cross-sectional population-level comparison between individuals from 1997-1998 and 2004-2005. Study participants were individuals aged 5 to 56 years identified as having asthma in the Medical Expenditure Panel Survey (MEPS). The main outcome measures were a controller-to-total asthma medication ratio greater than 0.5 and asthma exacerbation rates (dispensing of systemic corticosteroid or emergency department visit/hospitalization for asthma) in 1997-1998 compared with 2004-2005. RESULTS: The proportion of individuals with a controller-to-total asthma medication ratio greater than 0.5, when adjusted for other demographic factors, has improved by 16.1% (95% CI: 10.8%, 21.3%) for all individuals from 1997-1998 to 2004-2005. Annual asthma exacerbation rates did not change significantly in any group from 1997-1998 to 2004-2005 (0.27/year to 0.23/year). African American and Hispanic individuals with asthma had higher asthma exacerbation rates and a lower proportion with a controller-to-total asthma medication ratio greater than 0.5 than whites in both 1997-1998 and 2004-2005; however, these differences were not statistically significant. CONCLUSIONS: An increase in asthma controller-to-total medication ratio in a sample reflective of the US population was not associated with a decreased asthma exacerbation rate comparing 1997-1998 and 2004-2005.
BACKGROUND: The relationship between asthma controller medication use and exacerbation rates over time is unclear at the population level. OBJECTIVE: To estimate the change in asthma controller medication use between 2 time periods as measured by the controller-to-total asthma medication ratio and its association with changes in asthma exacerbation rates between 1997-1998 and 2004-2005. METHODS: The study design was a cross-sectional population-level comparison between individuals from 1997-1998 and 2004-2005. Study participants were individuals aged 5 to 56 years identified as having asthma in the Medical Expenditure Panel Survey (MEPS). The main outcome measures were a controller-to-total asthma medication ratio greater than 0.5 and asthma exacerbation rates (dispensing of systemic corticosteroid or emergency department visit/hospitalization for asthma) in 1997-1998 compared with 2004-2005. RESULTS: The proportion of individuals with a controller-to-total asthma medication ratio greater than 0.5, when adjusted for other demographic factors, has improved by 16.1% (95% CI: 10.8%, 21.3%) for all individuals from 1997-1998 to 2004-2005. Annual asthma exacerbation rates did not change significantly in any group from 1997-1998 to 2004-2005 (0.27/year to 0.23/year). African American and Hispanic individuals with asthma had higher asthma exacerbation rates and a lower proportion with a controller-to-total asthma medication ratio greater than 0.5 than whites in both 1997-1998 and 2004-2005; however, these differences were not statistically significant. CONCLUSIONS: An increase in asthma controller-to-total medication ratio in a sample reflective of the US population was not associated with a decreased asthma exacerbation rate comparing 1997-1998 and 2004-2005.
Authors: Kohei Hasegawa; Yusuke Tsugawa; Sunday Clark; Carly D Eastin; Susan Gabriel; Vivian Herrera; Jane C Bittner; Carlos A Camargo Journal: Chest Date: 2016-04-04 Impact factor: 9.410
Authors: Matthew A Rank; Ryan Johnson; Megan Branda; Jeph Herrin; Holly van Houten; Michael R Gionfriddo; Nilay D Shah Journal: Chest Date: 2015-09 Impact factor: 9.410
Authors: Elliot Israel; Juan Carlos Cardet; Jennifer K Carroll; Anne L Fuhlbrigge; Wilson D Pace; Nancy E Maher; Lilin She; Frank W Rockhold; Maureen Fagan; Victoria E Forth; Paulina Arias Hernandez; Brian K Manning; Jacqueline Rodriguez-Louis; Joel B Shields; Tamera Coyne-Beasley; Barbara M Kaplan; Cynthia S Rand; Wilfredo Morales-Cosme; Michael E Wechsler; Juan P Wisnivesky; Mary White; Barbara P Yawn; M Diane McKee; Paula J Busse; David C Kaelber; Sylvette Nazario; Michelle L Hernandez; Andrea J Apter; Ku-Lang Chang; Victor Pinto-Plata; Paul M Stranges; Laura P Hurley; Jennifer Trevor; Thomas B Casale; Geoffrey Chupp; Isaretta L Riley; Kartik Shenoy; Magdalena Pasarica; Rafael A Calderon-Candelario; Hazel Tapp; Ahmet Baydur Journal: Contemp Clin Trials Date: 2020-12-11 Impact factor: 2.226
Authors: John M Wiecha; William G Adams; Denis Rybin; Maria Rizzodepaoli; Jeremy Keller; Jayanti M Clay Journal: BMC Pulm Med Date: 2015-02-25 Impact factor: 3.317